Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer

Ketch et al. JCO PO 2025

Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients With Resected Stages I to III Colon Ca

Cohen et al. Annals of Surgery 2025

Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)

Honoré N, et al. ESMO 2025

Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma

Zhang Y, et al. Biomedicines. 2025

Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Ca

Abdelrahim M, et al. JCO Preci Oncol. 2025

Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy

Kim J, et al. Cancers 2025

Targeting CD38 in Subclinical Antibody-mediated Rejection in HLA-incompatible Kidney Transplantation: A Case Report

Refining the interpretation of variants of uncertain significance in hereditary cancer screening through integrated RNA sequencing

Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcin

Zaanan et al. Nat Commun, 2025

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA

Powles et al, ASCO 2025

Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma

Ansstas et al, ASCO 2025

Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 t

Mukhtar et al, ASCO 2025

Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)

Razavi et al, ASCO 2025

Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy

Pusztai et al, ASCO 2025

Zaanan 2025 Nature Communications

Abdelrahim 2025 ctDNA and HCC

Nasca et al. TRINITY Study Protocol - 2025 BMC Cancer

Zhang et al. Pancreatic Cancer - Biomedicines 2025

Carrier screening for Alport syndrome: The clinical importance of heterozygosity for pathogenic or likely pathogenetic variants

Souter, Vivienne; et al. J Genet Couns. 2025